Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer

Summary

An Italian randomized controlled trial parallel-group in patients with a malignant tumor of the right or proximal transverse colon requiring right hemicolectomy.

Conditions

• Colon Cancer

Interventions

PROCEDURE

Conventional Right hemicolectomy (Non-CME)

Transecting the Ileocolic Vein and Artery close to the Superior Mesenteric Vessels without clearing the superior mesenteric vein (SMV) from the adipose tissue. Transecting the Right Colic Vein and Artery and superior right colic vein (when present) peripherally. Transecting the Right branches of the Middle Colic Vein (MCV) and the Middle Colic Artery (MCA) peripherally, without clearing the main trunk of the MCV and the MCA. The Right Gastroepiploic Vein and artery are never transacted.

PROCEDURE

Right hemicolectomy with CME+CVL

Separation of the visceral fascia from the parietal fascia by sharp dissection leaving intact mesocolon coverage. Transecting the supplying vessels at their origin from the main vessels, particularly: * The Ileocolic Vessels, The Right Colic Vessels,The superior right colic vein (when present), The Right branches of the Middle Colic Vein and of the Middle Colic Artery * The MCV and MCA at their origin in case of cancer of the hepatic flexure or of the proximal third of the transverse colon, as well as The Right Gastroepiploic Vessels at their origin from the gastrocolic trunk of Henle (GCTH) and the gastroduodenal artery. The SMV should be cleared from all adipose tissue all along its anterior surface until its intrapancreatic entrance.

Sponsors & Collaborators

• Federico II University

  collaborator OTHER

• Agnelli Hospital, Italy

  collaborator OTHER

• Ospedale della Misericordia

  collaborator OTHER

• Candiolo Cancer Institute - IRCCS

  collaborator OTHER

• Maggiore Bellaria Hospital, Bologna

  collaborator OTHER

• Università degli Studi di Ferrara

  collaborator OTHER

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS

  collaborator OTHER

• Azienda Ospedaliera Universitaria Policlinico "G. Martino"

  collaborator OTHER

• Ospedale Policlinico San Martino

  collaborator OTHER

• University of Rome Tor Vergata

  collaborator OTHER

• S. Andrea Hospital

  collaborator OTHER

• European Institute of Oncology

  collaborator OTHER

• University of Turin, Italy

  lead OTHER

Principal Investigators

• Maurizio Degiuli, Professor · University of Turin, Department of Oncology

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-07-13

Primary Completion

2027-01-01

Completion

2027-01-01

Countries

• Italy

Study Locations